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Objectives: Presently, linaclotide is the only EMA approved therapy indicated for 
the treatment of irritable bowel syndrome with constipation (IBS-C). This study 
sought to determine the cost-effectiveness of linaclotide compared to antidepres-
sants for the treatment of adults with moderate to severe IBS-C who have previ-
ously received antispasmodics and/or laxatives from the perspective of the Scottish 
National Health System (NHS). MethOds: A Markov model was created to estimate 
costs and QALYs over a 5-year time horizon from the perspective of NHS Scotland. 
Health states were based on treatment satisfaction (satisfied, moderately satisfied, 
not satisfied) and death. Transitions between states were based on satisfaction data 
from the linaclotide pivotal studies (MCP-103-302 and LIN-MD-31) and Scottish 
general all-cause mortality statistics. Treatment costs were calculated from the 
British National Formulary. NHS resource use and disease-related costs for each 
health state were estimated from Scottish clinician interviews in combination with 
NHS Reference costs. Quality of life was based on EQ-5D data collected from the 
pivotal studies. Costs and QALYs were discounted at 3.5% per annum. Uncertainty 
was explored through extensive deterministic and probabilistic sensitivity analy-
ses. Results: Over a 5-year time horizon, the additional costs and QALYs with 
linaclotide were £659 and 0.089, resulting in an incremental cost-effectiveness ratio 
of £7,370 per QALY versus antidepressants. Results were most sensitive to health 
state transitions probabilities, NHS resource use assumptions and health state 
utilities. Threshold analyses showed that the effectiveness of linaclotide would 
have to be at least 11% lower than the base case to exceed a willingness-to-pay 
threshold (WTP) of £20,000 per QALY. Based on the probabilistic sensitivity analysis, 
the likelihood that linaclotide was cost-effective at a WTP of £20,000 per QALY was 
74%. cOnclusiOns: Linaclotide is a cost-effective treatment for adults with mod-
erate to severe IBS-C who have previously received antispasmodics and/or laxatives.
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Objectives: To assess the cost-effectiveness of treating chronic HCV infection 
(genotype 1) with currently available telaprevir+pegylated interferon alpha/ribavirin 
(TPR) compared to waiting for new regimens with improved efficacy (hypothetical 
treatment assumed) currently in development from the French health care perspec-
tive. MethOds: A Markov model tracked the adult naïve HCV+ French population 
over a lifetime horizon. Model health-states are defined by METAVIR fibrosis stage 
(F0-F4) and complications of advanced HCV (decompensated cirrhosis, hepatocel-
lular carcinoma, liver transplant, and death). During each 1-year cycle, individu-
als may remain in the current health-state, respond to treatment or progress, at 
probabilities determined by disease status, age at infection, current age, gender, 
and treatment received. Individuals were eligible for treatment in F2-F4. Transition 
probabilities, treatment efficacy, health-state utilities, resource utilization and costs 
were derived from published literature and standard French sources. The efficacy 
of a new hypothetical treatment regimen was based on currently published results; 
cost for the new treatment was assumed at € 50,000 for a full treatment (excluding 
PR backbone). Results: A treatment lag of 1, 2, and 3 years resulted in 142,777 indi-
viduals, 140,417 individuals, and 137,930 individuals being treated by the new regi-
men, respectively, versus 145,010 with immediate TPR treatment. The new treatment 
option resulted in additional life years saved (range 11,230-27,536), QALYs gained 
(range 12,528-29,359), and prevented more HCV-related deaths (range 3,839-5,756). 
Total costs incurred were higher for the new regimen versus TPR, from the health 
care perspective. ICERs were € 58,294.49/QALY, € 73,295.59/QALY, and € 107,403.02/
QALY gained for a 1, 2, and 3 year treatment lag, respectively. cOnclusiOns: These 
findings suggest waiting for new regimens currently in development should not be 
the most efficient choice to be considered by French Health care system. Waiting 
for new treatments should yield better clinical outcomes, but with higher costs and 
ICERS that may be challenging for the payer.
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Objectives: This study had a dual objective: verify the improvements in qual-
ity of life (QoL) due to biological drugs administration and evaluate their cost-
effeffectiveness versus the standard steroid-based therapy in Crohn’s Disease 
(CD). High-cost biological drugs’ efficacy is well-established, but they still lack of 
cost-effectiveness studies. MethOds: A survey was prepared with clinicians and 
pharmacoeconomists and administered in 9 centers in Italy. The questionnaire 
was set up to detect QoL through a Visual Analogue Scale and EQ-5D and to assess 
patients’ profile (age, gender, job) and clinical features (time-to-first diagnosis, cur-
rent and at-diagnosis Montreal classification, current and at-diagnosis treatments, 
past surgical procedures, hospitalizations). Collected data were then used in a sta-
tistical regression model and an economic assessment complete of probabilistic 
sensitivity analysis was performed comparing costs and utilities of the considered 
treatments. Results: A total of 348 questionnaires were collected, giving back a 
Objectives: Establish the potential resource and cost savings from using ePTFE 
covered stent-grafts configured for TIPS (SG) compared to bare metal stents (BMS). 
Most centres have adopted SGs to treat portal hypertension because of their 
reduced re-intervention rates, elimination of regular monitoring of patency and 
improved survival. However there is no published economic analysis identifying 
the related cost consequences. Understanding the improved efficiencies is essen-
tial in the current financial environment. MethOds: A Markov economic model 
was developed to measure the incremental costs of the initial procedure and 
re-interventions with SG compared to BMS. Re-intervention procedures included 
angioplasty (67%), introducing a balloon expandable stent (22%) or a second stent 
(10%). The adverse events were hepatic encephalopathy and clinical relapse. 
Clinical data came mainly from a published RCT (Bureau 2007), whilst health care 
costs were from UK national databases. Results: Compared to BMS, using SG in 
TIPS resulted in a cost saving of over £1,150 per patient over 2 years. Modelling 100 
patients, compared to BMS, the SG cohort had 25 fewer re-interventions including 
angioplasties, saving 41 hours staff time in theatre and 16 inpatient days; with 
fewer cases of encephalopathy (16), recurrent ascites (8), variceal bleeds (5) and a 
markedly reduced mortality (13). cOnclusiOns: The model showed that ePTFE 
covered stent-grafts configured for TIPS reduced mortality and re-interventions, 
saved theatre time and bed-days, and reduced overall costs despite the higher 
initial device cost.
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Objectives: In 2011 EMA approved Boceprevir and Telaprevir with PegIFN and 
Ribavirin for the treatment of Genotype 1 Chronic Hepatitis C patients. In 2013 
the Greek and other European HCV Guidelines recommend treatment alloca-
tion in G1 naïve patients according to the IL28B genotype or the RVR profile. 
Local studies indicate that the IL28B-CC and the RVR (+) rates are approximately 
30%. The objective of this study was to implement this guidance and examine 
whether triple therapy with PegIFNa-2a+RBV and the two protease inhibitors, 
Boceprevir or Telaprevir, constitutes a cost-saving option for the treatment of 
naïve G1 patients in the Greek health care setting. MethOds: For the needs 
of this analysis, a cost-consequence model was utilized, to compare the costs 
incurred when: i) patients with IL28B CC aplotype (30%) were treated with SoC 
(PegIFN alfa-2a + RBV) and patients with IL28B non-CC aplotypes (70%) were 
treated with triple therapy and ii) all patients are treated with triple therapy. 
The economic inputs are based on official and publically available sources while 
the clinical inputs are taken from published clinical trial results. The number of 
patients treated per year was provided by local bibliography. Results: The total 
cost to treat 509 naïve patients with triple therapy was € 13,8 million compared to 
€ 10.9 million to treat based on IL28B allocation, maintaining the same SVR rate 
of 70% for either of the treatment strategies. cOnclusiOns: This personalized 
approach based on a baseline predictor of response such as the IL28B profile was 
proven to be a cost-saving resource allocation choice compared to the option 
of treating all treatment naive patients with triple therapy, providing SVR rates 
of 70% and a constrain of cost for the Greek health care system of € 2,9 million/
year (aprox.25%).
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Objectives: To assess the cost-effectiveness of treating HCV infection (geno-
type 1) with telaprevir/pegylated interferon alpha/ribavirin (TPR) at METAVIR 
fibrosis stage F2 (“early”) versus delaying treatment until progression to F3 
(“delayed”) from the French health care perspective. MethOds: A Markov 
model tracked the HCV+ French population aged 40+ over a lifetime horizon to 
compare outcomes of early versus delayed treatment. Model health states are 
defined by fibrosis stage (F0-F4) and complications of advanced HCV includ-
ing decompensated cirrhosis, hepatocellular carcinoma, liver transplant, and 
death. During each 1-year cycle, individuals may remain in the current health 
state, respond to treatment or progress, at probabilities determined by disease 
status, age at infection, current age, gender, and treatment received. Transition 
probabilities, treatment efficacy, health-state utilities, resource utilization and 
costs were derived from published literature and standard French sources. Costs 
and outcomes were discounted at 4.0% for 30 years and 2% thereafter. Cost-
effectiveness was assessed as incremental cost per life year gained (LYG) and 
QALY gained. Results: An estimated 203,644 French residents aged 40+ years 
are diagnosed with HCV in 2013. Treating with TPR at F2 versus F3 is projected 
to result in 135,240 versus 113,728 individuals treated, at an incremental life-
time cost of € 654.65M from the French health care perspective. Early treatment 
avoided 2,205 HCV-related deaths and saved 11,384 life-years, and 17,599 QALYs, 
at a cost of € 57,506/LYG and € 37,197/QALY gained. Results are most sensitive to 
efficacy parameters, time horizon, and discount rates and least sensitive to diag-
nosis and treatment parameters. cOnclusiOns: Treating HCV-infected indi-
viduals at F2 is expected to results in better clinical outcomes but at higher cost 
compared to delaying treatment until the individual progresses to F3. Earlier 
treatment with TPR should be considered as an efficient choice by the French 
health care system based on its estimated incremental cost-effectiveness ratio 
of € 37,197/QALY gained.
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which provided monthly EQ-5D measures, treatment duration, adverse events (diar-
rhoea) and responder status (abdominal pain/discomfort improvement ≥ 30% from 
baseline). Belgian EQ-5D tariffs were used to estimate utilities and trapezoidal rule 
to estimate QALYs. A Delphi panel including 6 general practitioners and 5 gastro-
enterologists provided the resource use for IBS-C patients in different treatment 
phases: controlled with 2nd line or new drug else non-responders. Patient-level 
costs were applied using first-order Monte-Carlo simulation (gamma distribution 
function; per treatment arm and responder status; health care payer perspective). 
A stopping rule was implemented at 4 weeks for linaclotide non-responders. A 
non-parametric bootstrap with 1000 replications was performed. The 2012 Belgian 
GDP per capita (€ 34,000) was used as willingness-to-pay threshold. Results: The 
responder rate at 4 weeks was 54.6% with linaclotide vs. 35.5% with SoC. There 
was on average 0.0129 QALYs gained per linaclotide patient vs SoC at 6 months 
(0.385 vs. 0.372), with an incremental cost of € 95 (€ 1,376 vs. € 1,280). The incremental 
cost-effectiveness ratio of was € 7,364/QALY. The diarrhoea costs were higher with 
linaclotide (+€ 19.4) while savings were observed in clinical management (-€ 132.2) 
compared to SoC. Using a willingness-to-pay threshold of € 34,000/QALY, 66% of the 
simulations were cost-effective. cOnclusiOns: Due to improvements in abdomi-
nal pain/discomfort complaints in patients receiving linaclotide, savings were gen-
erated in the clinical management of IBS-C compared to SoC. Using the GDP per 
capita as willingness-to-pay threshold, linaclotide seems a cost-effective alternative 
to today SoC of IBS-C in Belgium.
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Objectives: Capsule endoscopy (CE) is a minimally invasive endoscopic tech-
nology that uses a disposable capsule containing a small camera to monitor 
and diagnose disorders of the gastrointestinal tract such as Crohn’s disease and 
obscure gastrointestinal bleeding. This study examines cost-effectiveness of CE 
(PillCam®, Given Imaging) for the diagnosis of small bowel Crohn’s disease in 
Australia. MethOds: A modelled cost-utility analysis of CE vs. no CE followed 
by empiric treatment is performed. The population under consideration consists 
of patients with a clinical suspicion of Crohn’s disease despite non-confirmatory 
results with prior endoscopic/radiologic tests. Due to a lack of alternative diagnos-
tic options, many of these patients currently receive empiric treatment, whereby 
a diagnosis is achieved based on long-term response to therapy for Crohn’s dis-
ease. CE increases the proportion of patients who receive a confirmed diagnosis 
for Crohn’s disease or for other bowel conditions (represented by irritable bowel 
syndrome in the model), thereby allowing more patients to promptly receive 
a correct treatment and thus improving the down-stream treatment effective-
ness. The administration of correct and effective treatment, as aided by CE, thus 
produces additional QALYs and potential cost savings, which are captured by the 
current model. The model has a 12-month time horizon and takes the perspec-
tive of Australian health care system. Results: CE is estimated to produce 0.057 
additional QALYs over the 12-month period. The additional cost of CE is in part 
offset by cost savings arising from the improved treatment selection. The incre-
mental cost-effectiveness ratio (ICER) is estimated to be $23,672 per additional 
QALY. cOnclusiOns: The current model suggests CE is highly cost-effective. 
Importantly, the target patient population currently experience a unique and 
special unmet clinical need because the currently funded endoscopic/radiologic 
technologies are unable to provide a confirmed diagnosis. The evidence for cost-
effectiveness clearly supports that CE represents good value for money.
PGI35
thE Cost-utILIty of fIdaxomICIn as ComParEd to CurrEnt standard 
trEatmEnt In thE manaGEmEnt of CLostrIdIum dIffICILE InfECtIons 
In bELGIum
Lamotte M.1, Vellopoulou K.2, Richir K.3, Smets J.3, Grabe K.4, Coppens K.3
1IMS Health HEOR, Vilvoorde, Belgium, 2IMS Health, Vilvoorde, Belgium, 3Astellas, Brussels, 
Belgium, 4Astellas Pharma Europe Ltd., Chertsey, UK
Objectives: Clostridium difficile infection (CDI) is one of the most common hos-
pital acquired infections in industrialised countries. CDI is responsible for severe 
morbidity, partly driven by the high proportion of patients experiencing a recur-
rence after an initial successful response to treatment. In Belgium, CDI incidence 
and mortality has more than doubled between 1998 and 2007. The aim of this study 
was to assess the cost-utility of fidaxomicin as compared to current standard treat-
ment for managing CDI in Belgium. MethOds: A Markov model with a 1-year time 
horizon and 10-day cycles was developed to compare fidaxomicin, metronidazole 
and vancomycin in patients with all CDI and two subpopulations (severe CDI and 
first recurrence of CDI). Clinical data from two pooled published phase-3 trials 
(fidaxomicin vs. vancomycin) were used along a mixed treatment comparison of 
fidaxomicin vs. metronidazole. Treatment paths and data input were approved dur-
ing an advisory board. Costs of first episode and recurrent CDI hospitalizations were 
taken from the IMS Hospital Disease Database. Cost per quality-adjusted life-year 
(QALY) gained was calculated from the health care payer perspective. Results: The 
model showed cost savings and QALY gained versus vancomycin and metronida-
zole. Fidaxomicin versus an average of these comparators delivered benefits for all 
CDI patients (-1,100€ ; 0.008 QALY), for severe CDI (-1,300€ ; 0.009 QALY) and for first 
recurrence CDI (-1,500€ ; 0.009 QALY). One-way sensitivity analyses revealed that 
time horizon and the odds ratio of recurrence with fidaxomicin had most affect 
on the results. Applying a cost-effectiveness threshold of € 30,000 per QALY gained, 
probabilistic sensitivity analysis showed acceptable cost-effectiveness in 80% of all 
CDI cases. cOnclusiOns: Based on the available clinical data the model showed 
that fidaxomicin dominates vancomycin and metronidazole generating additional 
QALYs with cost-savings not only in patients with all CDI, but also in subpopulations 
with severe CDI or a first recurrence.
population with a mean age of 42, 52% male, 58% actively working, 52% undergone 
surgical interventions, and 66% being already administered previous therapies. 
The mean number of outpatients visits was 4.15/year, with 0.23 hospitalizations/
year. At diagnosis, the 55% of patients were treated with steroids, while only the 
3% with biological drugs. At the time of survey administration, the 9% of patients 
were treated with steroids, and the 50% with biological drugs. The statistical model 
showed a significant QoL improvement due to biological drugs therapy of about 6%. 
The economic assessment showed biological drugs to be cost-effective only in more 
severe settings of patients (€ 26.000 – 38.000 /QALY), but not in mild and moderate 
CD (€ 58.000 to 328.000 /QALY). cOnclusiOns: The results of the analysis, based 
on simulation models and real practice data, are consistent with evidences from 
other countries and thus biological drugs can be considered a good health care 
investment in severe cases of CD.
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Objectives: To compare the cost-effectiveness of therapy of different forms of GERD 
with esomeprazole and other proton pump inhibitors (PPIs) in Poland. MethOds: 
Results of clinical trials with esomeprazole in comparison with equivalent doses of 
other PPIs in the treatment of erosive esophagitis (EE - 6 RCTs), non-erosive reflux 
disease (NERD – 1 RCT) and GERD maintenance therapy (2 RCTs) were systemati-
cally reviewed. Meta-analysis was conducted as appropriate, relative risk values 
were calculated. Cost data derived from Polish Ministry of Health and pharma-
cies in Wroclaw. Cost effectiveness ratios and incremental cost effectiveness ratios 
were assessed for 100 patients. Results: In the treatment of EE esomeprazole 
was significantly more effective than other PPIs. For 4 weeks therapy ICER values 
(esomeprazole 40 mg vs. omeprazole 20 mg and pantoprazole 40 mg) were 614 PLN 
and 906.33 PLN respectively if original and generic esomeprazole products were 
taken into account and 118.22 PLN and 162.67 for generics. For 8 weeks therapy 
ICER values (esomeprazole 40 mg vs. omeprazole 20 mg, lansoprazole 30 mg and 
pantoprazole 40 mg) were: 430.45 PLN, 329.47 PLN and 325.33 PLN (for generics 
and original esomeprazole) and 1869.58 PLN, 2677.89 PLN and 1812.67, respectively 
for generics. Differences in effectiveness of NERD therapy with esomeprazole and 
other PPIs were not statistically significant. The replacement of pantoprazole 20 mg 
with more effective esomeprazole 20 mg in the 6-month maintenance therapy was 
associated with a marginal cost of 3078.01 PLN (only generics included) and 4590.91 
PLN (for original esomeprazole and generics) respectively. cOnclusiOns: 1) For 
4 and 8 weeks therapy of EE esomeprazole has to be recognized as a cost-effective 
option. 2) In the NERD treatment the choice of PPI should be based on the price of 
medicament. 3) The use of esomeprazole in GERD maintenance therapy is associ-
ated with a very high ICER.
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Objectives: To assess the cost-effectiveness of retreatment with pegylated inter-
feron and ribavirin in combination with boceprevir of HCV genotype 1 patients, who 
failed to respond to previous treatment, in comparison with absence of retreatment 
and retreatment with pegylated interferon and ribavirin. MethOds: We performed 
cost-effectiveness analysis. Based on the published data we modeled the number 
of long-term unfavorable outcomes of HCV (liver cirrhosis, hepatocellular carci-
noma and death) in the hypothetic cohort of HCV genotype 1 patients following 
one of three retreatment strategies: “no treatment” (NT), “peginterferon+ribavirin” 
(PR) and “peginterferon + ribavirin + boceprevir” (PRB). We have evaluated direct 
medical costs for a short-term (only cost of HCV retreament) and for a long-term 
(costs of medical care for adverse outcomes) periods for all strategies. Costs were 
estimated on the basis of average price for the drugs and reimbursement rates 
for medical services in the compulsory medical insurance system. Incremental 
cost-effectiveness ratio (ICER) for PR and PRB strategies vs NT were calculated as 
additional cost per unfavorable outcome avoided. Results: It is expected that in 
hypothetic cohort of 10000 HCV genotype 1 patients 58,1% would fail to respond to 
the treatment. The estimated costs of retreatment for this group were EURO 69,07 
mln in case of PR strategy and EURO 235,58 mln for PRB. The cumulative number 
of unfavorable outcomes of HCV during 25-year period would be 5075 cases for NT 
strategy, 4262 for PR and 2012 for PRB. The long-term costs of NT strategy were EURO 
205,35 mln, EURO 168,37 mln in case of PR strategy and EURO 81,4 mln for PRB. ICER 
for PR strategy was EURO 44532 and for PRB - EURO 36379 per unfavorable outcome 
avoided. cOnclusiOns: The use of PRB strategy is efficient as it allows reducing 
the number of unfavorable outcomes of HCV at a lesser cost.
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Objectives: Linaclotide is the first drug that received EMA approval in the man-
agement of irritable bowel syndrome in its constipation form (IBS-C). We aimed 
at estimating the cost-utility of linaclotide, compared to standard of care (SoC) 
in Belgium. MethOds: The analysis was conducted using data from a 6-month 
randomized trial of linaclotide 290µg once daily (N= 401) versus placebo (N= 403), 
